IL264628A - Combination of fxr agonists - Google Patents
Combination of fxr agonistsInfo
- Publication number
- IL264628A IL264628A IL264628A IL26462819A IL264628A IL 264628 A IL264628 A IL 264628A IL 264628 A IL264628 A IL 264628A IL 26462819 A IL26462819 A IL 26462819A IL 264628 A IL264628 A IL 264628A
- Authority
- IL
- Israel
- Prior art keywords
- combination
- fxr agonists
- fxr
- agonists
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662394446P | 2016-09-14 | 2016-09-14 | |
| PCT/IB2017/055503 WO2018051230A1 (en) | 2016-09-14 | 2017-09-12 | Combination of fxr agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL264628A true IL264628A (en) | 2019-02-28 |
Family
ID=60043251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL264628A IL264628A (en) | 2016-09-14 | 2019-02-03 | Combination of fxr agonists |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20210290610A1 (ja) |
| EP (1) | EP3512558A1 (ja) |
| JP (1) | JP6878596B2 (ja) |
| KR (1) | KR102218498B1 (ja) |
| CN (1) | CN109689105A (ja) |
| AR (1) | AR109652A1 (ja) |
| AU (2) | AU2017328999B2 (ja) |
| BR (1) | BR112019004684A2 (ja) |
| CA (1) | CA3036760A1 (ja) |
| CL (1) | CL2019000625A1 (ja) |
| CO (1) | CO2019002245A2 (ja) |
| CR (1) | CR20190125A (ja) |
| EC (1) | ECSP19016844A (ja) |
| IL (1) | IL264628A (ja) |
| JO (1) | JOP20190040A1 (ja) |
| MX (1) | MX2019003021A (ja) |
| PE (1) | PE20190972A1 (ja) |
| PH (1) | PH12019500326A1 (ja) |
| RU (1) | RU2019110780A (ja) |
| SG (1) | SG11201900651PA (ja) |
| TW (1) | TW201811372A (ja) |
| WO (1) | WO2018051230A1 (ja) |
| ZA (1) | ZA201900528B (ja) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110418641A (zh) * | 2017-02-24 | 2019-11-05 | 基恩菲特公司 | 用于组合疗法的药物组合物 |
| CN112203658A (zh) * | 2018-05-31 | 2021-01-08 | 诺华股份有限公司 | 包含卓匹非索和塞尼韦洛的组合 |
| US20220249469A1 (en) * | 2019-07-18 | 2022-08-11 | Enyo Pharma | Improved treatment using eyp001 |
| TW202135812A (zh) * | 2019-12-20 | 2021-10-01 | 瑞士商諾華公司 | 使用整聯蛋白抑制劑組合治療肝臟疾病 |
| CN112402430A (zh) * | 2020-12-11 | 2021-02-26 | 大连医科大学 | 泽泻醇b-23-醋酸酯在预防和治疗急性肾损伤中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6987121B2 (en) * | 2002-04-25 | 2006-01-17 | Smithkline Beecham Corporation | Compositions and methods for hepatoprotection and treatment of cholestasis |
| CA2743030C (en) * | 2008-11-26 | 2013-10-22 | Pfizer Inc. | 3-aminocyclopentanecarboxamides as chemokine receptor modulators |
| US8383812B2 (en) | 2009-10-13 | 2013-02-26 | Bristol-Myers Squibb Company | N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes |
| CU24152B1 (es) * | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| PE20160682A1 (es) * | 2013-11-05 | 2016-07-23 | Novartis Ag | Composiciones y metodos para modular los receptores x farnesoides |
| WO2015138986A1 (en) * | 2014-03-13 | 2015-09-17 | Salk Institute For Biological Studies | Fxr agonists and methods for making and using |
| AU2015314830B2 (en) * | 2014-09-12 | 2021-01-07 | Tobira Therapeutics, Inc. | Cenicriviroc combination therapy for the treatment of fibrosis |
| EP3233083A1 (en) * | 2014-12-18 | 2017-10-25 | Novartis AG | Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases |
| PT3419624T (pt) * | 2016-02-22 | 2021-04-07 | Novartis Ag | Métodos para utilizar agonistas de fxr |
-
2017
- 2017-06-16 JO JOP/2019/0040A patent/JOP20190040A1/ar unknown
- 2017-09-12 CR CR20190125A patent/CR20190125A/es unknown
- 2017-09-12 MX MX2019003021A patent/MX2019003021A/es unknown
- 2017-09-12 KR KR1020197009426A patent/KR102218498B1/ko active IP Right Grant
- 2017-09-12 WO PCT/IB2017/055503 patent/WO2018051230A1/en active Application Filing
- 2017-09-12 PE PE2019000497A patent/PE20190972A1/es unknown
- 2017-09-12 US US16/332,446 patent/US20210290610A1/en not_active Abandoned
- 2017-09-12 CN CN201780056097.XA patent/CN109689105A/zh active Pending
- 2017-09-12 SG SG11201900651PA patent/SG11201900651PA/en unknown
- 2017-09-12 JP JP2019535998A patent/JP6878596B2/ja active Active
- 2017-09-12 BR BR112019004684A patent/BR112019004684A2/pt not_active IP Right Cessation
- 2017-09-12 CA CA3036760A patent/CA3036760A1/en not_active Abandoned
- 2017-09-12 EP EP17781186.6A patent/EP3512558A1/en not_active Withdrawn
- 2017-09-12 RU RU2019110780A patent/RU2019110780A/ru not_active Application Discontinuation
- 2017-09-12 AU AU2017328999A patent/AU2017328999B2/en not_active Ceased
- 2017-09-14 AR ARP170102541A patent/AR109652A1/es unknown
- 2017-09-14 TW TW106131530A patent/TW201811372A/zh unknown
-
2019
- 2019-01-25 ZA ZA2019/00528A patent/ZA201900528B/en unknown
- 2019-02-03 IL IL264628A patent/IL264628A/en unknown
- 2019-02-15 PH PH12019500326A patent/PH12019500326A1/en unknown
- 2019-03-11 EC ECSENADI201916844A patent/ECSP19016844A/es unknown
- 2019-03-12 CL CL2019000625A patent/CL2019000625A1/es unknown
- 2019-04-15 CO CONC2019/0002245A patent/CO2019002245A2/es unknown
-
2020
- 2020-03-19 AU AU2020201980A patent/AU2020201980A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2019003021A (es) | 2019-09-26 |
| CN109689105A (zh) | 2019-04-26 |
| PH12019500326A1 (en) | 2019-11-11 |
| KR102218498B1 (ko) | 2021-02-22 |
| CO2019002245A2 (es) | 2019-05-31 |
| ECSP19016844A (es) | 2019-03-29 |
| CL2019000625A1 (es) | 2019-05-17 |
| EP3512558A1 (en) | 2019-07-24 |
| ZA201900528B (en) | 2021-06-30 |
| AU2020201980A1 (en) | 2020-04-09 |
| RU2019110780A (ru) | 2020-10-15 |
| SG11201900651PA (en) | 2019-04-29 |
| AR109652A1 (es) | 2019-01-09 |
| TW201811372A (zh) | 2018-04-01 |
| US20210290610A1 (en) | 2021-09-23 |
| PE20190972A1 (es) | 2019-07-09 |
| CA3036760A1 (en) | 2018-03-22 |
| CR20190125A (es) | 2019-06-04 |
| BR112019004684A2 (pt) | 2019-05-28 |
| AU2017328999B2 (en) | 2019-12-19 |
| WO2018051230A1 (en) | 2018-03-22 |
| AU2017328999A1 (en) | 2019-02-21 |
| JOP20190040A1 (ar) | 2019-03-10 |
| JP2019526644A (ja) | 2019-09-19 |
| JP6878596B2 (ja) | 2021-05-26 |
| KR20190044666A (ko) | 2019-04-30 |
| RU2019110780A3 (ja) | 2020-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1257647A1 (zh) | 使用fxr促效劑之方法 | |
| HK1257649A1 (zh) | 使用fxr激動劑的方法 | |
| HK1255162A1 (zh) | 愛帕琳肽受體激動劑及使用方法 | |
| IL251584A0 (en) | Dihydropyrrolopyridines ror-gamma inhibitors | |
| IL246902B (en) | Dihydropyrrolopyridine ror–gamma inhibitors | |
| ZA201604272B (en) | Inhibitors of glutaminase | |
| HK1257648A1 (zh) | Fxr促效劑之使用方法 | |
| IL264628A (en) | Combination of fxr agonists | |
| IL265628A (en) | Solid state forms of valbenazine | |
| IL246979A0 (en) | Crystalline forms of sofosbuvir | |
| LT3217978T (lt) | Kompozicijos, apimančios pakeistą benzofurochinoliziną ir alfa2-adrenerginius agonistus | |
| GB201720445D0 (en) | Use of TRPV1 agonists | |
| GB201620933D0 (en) | Use of TRPV1 agonists | |
| GB201507707D0 (en) | Components and methods for formation of components | |
| GB201400386D0 (en) | Agonists |